Results obtained by Gilead and Arcus could rekindle interest in the anti-TIGIT modality, which has seen many setbacks in the ...
Cognivia Signal will try to predict which patients are at risk of dropping out to give sponsors the opportunity to intervene.
MFN-driven drug price reductions in the US are unlikely to have a big impact pharma R&D spending, experts agree.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback